The REVAMP trial: key questions remain - Authors' reply

Affiliations

¹ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Diagnostic Haematology, The Royal Melbourne Hospital, Parkville, VIC, Australia; Clinical Haematology, The Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia. Electronic address: pasricha.s@wehi.edu.au.
² Training and Research Unit of Excellence, Blantyre, Malawi; Department of Public Health, School of Public and Global Health, Kamuzu University of Health Sciences, Blantyre, Malawi.
³ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medicine at the Peter Doherty Institute, The University of Melbourne, Parkville, VIC, Australia.
⁴ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.

Comment

Sant-Rayn Pasricha et al. Lancet. 2024.

. 2024 Jan 6;403(10421):29-30.

doi: 10.1016/S0140-6736(23)01915-3.

¹ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Diagnostic Haematology, The Royal Melbourne Hospital, Parkville, VIC, Australia; Clinical Haematology, The Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia. Electronic address: pasricha.s@wehi.edu.au.
² Training and Research Unit of Excellence, Blantyre, Malawi; Department of Public Health, School of Public and Global Health, Kamuzu University of Health Sciences, Blantyre, Malawi.
³ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medicine at the Peter Doherty Institute, The University of Melbourne, Parkville, VIC, Australia.
⁴ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.

No abstract available

Comment on

The REVAMP trial: key questions remain.
Liang D, Lin Y, He L. Liang D, et al. Lancet. 2024 Jan 6;403(10421):28. doi: 10.1016/S0140-6736(23)01917-7. Lancet. 2024. PMID: 38184332 No abstract available.
The REVAMP trial: key questions remain.
Froeliger A, Madar H, Bouchghoul H, Deneux-Tharaux C, Sentilhes L. Froeliger A, et al. Lancet. 2024 Jan 6;403(10421):28. doi: 10.1016/S0140-6736(23)01918-9. Lancet. 2024. PMID: 38184333 No abstract available.
The REVAMP trial: key questions remain.
Sato T, Yanagisawa R. Sato T, et al. Lancet. 2024 Jan 6;403(10421):28-29. doi: 10.1016/S0140-6736(23)01919-0. Lancet. 2024. PMID: 38184334 No abstract available.